Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-05-01

Clinical Trial Update: Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of anti-MAP therapy in adults with Crohn's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Anti-MAP therapy

Snippet

Sponsor: RedHill Biopharma Limited | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-05-01